Literature DB >> 17428240

Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.

Tobias Klatte1, Malte Böhm, Thomas Nelius, Stephanie Filleur, Frank Reiher, Ernst Peter Allhoff.   

Abstract

OBJECTIVE: To evaluate peri-operative peripheral and renal venous plasma levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor type BB (PDGF-BB), transforming growth factor (TGF)-beta1, endostatin, and thrombospondin-1 (TSP-1) in relation to pathological variables and prognosis, as pro- and anti-angiogenic factors are important for tumour growth and treatment of patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: The study included 74 consecutive patients with sporadic RCC who had tumour nephrectomy. Peripheral venous blood was drawn 1 day before, immediately and 1, 3 and 5 days after surgery. Renal venous blood was collected in a subgroup of 33 patients during surgery. The variables were analysed using quantitative enzyme-linked immunoassay kits, and associated with pathological variables and disease-specific survival.
RESULTS: Soon after surgery, peripheral venous VEGF, PDGF-BB and TGF-beta1 levels were decreased, whereas endostatin levels were significantly increased. Renal venous VEGF, PDGF-BB and TGF-beta1 levels were higher than in the general venous blood pool. Renal venous VEGF levels were correlated with tumour diameter and associated with grade and vascular invasion. After a mean follow-up of 30 months, higher peripheral preoperative, early peripheral postoperative and renal venous VEGF levels were associated with a poorer prognosis. However, in a multivariate analysis only Tumour-Node-Metastasis stage and Eastern Cooperative Oncology Group performance status were independent prognosticators of disease-specific survival.
CONCLUSIONS: Circulating pro- and anti-angiogenic factors change early after nephrectomy. VEGF, PDGF-BB and TGF-beta1 are higher in the renal vein than in the general venous blood pool. Higher renal venous and peripheral levels of VEGF might be associated with a poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428240     DOI: 10.1111/j.1464-410X.2007.06871.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

Review 1.  Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.

Authors:  Xuwei Hong; Fei Li; Kaiqiang Tang; Shiyu Pang; Guangzheng Lin; Shi Li; Jiming Bao; Wanlong Tan
Journal:  Int Urol Nephrol       Date:  2016-02-09       Impact factor: 2.370

Review 2.  Prognostic factors in renal cell carcinoma.

Authors:  Alessandro Volpe; Jean Jacques Patard
Journal:  World J Urol       Date:  2010-04-03       Impact factor: 4.226

Review 3.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

4.  Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.

Authors:  M de Martino; K Hoetzenecker; H J Ankersmit; G A Roth; A Haitel; M Waldert; T Klatte
Journal:  Br J Cancer       Date:  2012-01-31       Impact factor: 7.640

5.  Change in plasma vascular endothelial growth factor after gamma knife radiosurgery for meningioma: a preliminary study.

Authors:  Seong-Hyun Park; Jeong-Hyun Hwang; Sung-Kyoo Hwang
Journal:  J Korean Neurosurg Soc       Date:  2015-02-26

Review 6.  Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis.

Authors:  Stepan M Esagian; Ioannis A Ziogas; Dimitrios Kosmidis; Mohammad D Hossain; Nizar M Tannir; Pavlos Msaouel
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.